ONCE-DAILY
Austedo® XR
(deutetrabenazine)
extended-release
6 mg, 12 mg, 18 mg, 24 mg, 30 mg,
36 mg, 42 mg, and 48 mg tablets

Flexibility for effective & tolerable control[2]



Additional administration information[2]:

- AUSTEDO XR can be taken with or without food
- AUSTEDO XR should be swallowed whole
- Tablets should not be chewed, crushed, or broken

Billing codes

ICD-10 CM Diagnosis Codes: G24.01 Tardive Dyskinesia (TD)
G10 Huntington's Chorea (HD)

AUSTEDO XR Dosage	10-digit NDC	11-digit NDC
12 mg	68546-471-56	68546-0471-56
18 mg	68546-479-56	68546-0479-56
24 mg	68546-472-56	68546-0472-56
30 mg	68546-473-56	68546-0473-56
36 mg	68546-474-56	68546-0474-56
42 mg	68546-475-56	68546-0475-56
48 mg	68546-476-56	68546-0476-56

IMPORTANT SAFETY INFORMATION (Continued)

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

Additional access & affordability

30-day Free Trial Voucher*

- **All new, non-sampled patients** can start AUSTEDO XR at no cost.

Copay Card†

- **Eligible patients with commercial insurance** may pay as little as $0 per month for continuing treatment with AUSTEDO XR.

Additional financial assistance

- **For Medicare Part D patients:** Patients who qualify for and utilize LIS pay no more than $11.20 per month.[5]
- **For uninsured or underinsured patients:** Teva Cares is an independent, non-profit program that provides AUSTEDO XR/AUSTEDO at no cost to eligible patients.†

Teva **Shared Solutions**® can help patients understand financial assistance options available to them.

covermymeds®

Access and Reimbursement Managers can provide education on the PA process through CoverMyMeds® at covermymeds.com

CoverMyMeds is a registered trademark of CoverMyMeds LLC.
LIS, low-income subsidy.
*Certain restrictions apply. Terms and conditions on **AUSTEDOcardform.com**.
†Patients must reside in the United States, meet insurance and income requirements, and have a valid prescription.

IMPORTANT SAFETY INFORMATION (Continued)

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

Please see additional Important Safety Information throughout and click here to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.

References: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. **2.** AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. **3.** Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. *Front Neurol.* 2022;13:773999. **4.** Frank S, Testa C, Edmondson MC, et al. The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. *CNS Drugs.* 2022;36(11):1207-1216. **5.** Medicare. Find your level of Extra Help (Part D). Accessed May 7, 2024. https://www.medicare.gov/basics/costs/help/drug-costs

teva

YOUR GUIDE TO GETTING PATIENTS STARTED WITH

ONCE-DAILY
Austedo® XR
(deutetrabenazine)
extended-release
6 mg, 12 mg, 18 mg, 24 mg, 30 mg,
36 mg, 42 mg, and 48 mg tablets

See inside for Rx details about:

New patients utilizing the 4-week Titration Kit (Sample or Retail Kit)

Switching patients to one pill, once-daily AUSTEDO XR

INDICATIONS AND USAGE

AUSTEDO XR and AUSTEDO are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease:
AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Please see additional Important Safety Information throughout and click here to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.

ONCE-DAILY
Austedo® XR
(deutetrabenazine)
extended-release
6 mg, 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, 42 mg, and 48 mg tablets

New patients utilizing the 4-week Sample Titration Kit

The Sample Titration Kit helps patients start and stay on track[1,2]*

Week 1: 12 mg once daily
Week 2: 18 mg once daily
Week 3: 24 mg once daily
Week 4: 30 mg once daily

	10-digit NDC	11-digit NDC
4-week Titration Kit	68546-477-29	68546-**0**477-29

Some patients may not complete the full 4-week Titration Kit.

See Transition Quick Reference Chart for complete AUSTEDO XR titration schedule.

Image shown is not actual 4-week Titration Kit.
*Notify pharmacy if patient has been sampled.

IMPORTANT SAFETY INFORMATION (Continued)

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

New, non-sampled patients utilizing the 4-week Retail Titration Kit

When sampling is not permitted, Retail Titration Kits are available at no cost with the 30-day Free Trial Voucher†:


Austedo XR | Shared Solutions®

30 DAYS FREE

*FREE TRIAL VOUCHER FOR NEW PATIENTS**

Bin:
PCN:
Group Member:
Member ID:

This Free Trial Voucher is not conditioned on any past, present, or future purchase, including refills. No purchase is required.

- Providers will submit prescription for Titration Kit (NDC: 68546-**0**477-29)
- Redeem Free Trial Voucher at **AUSTEDOcardform.com** and provide 4-week Titration Kit at no cost to patient
- Request Prior Authorization (PA) so patient can continue treatment after 30-day Free Trial Voucher use

Access Free Trial Voucher at AUSTEDOcardform.com. For questions or additional assistance, please call 1-844-308-5110

See additional information on access & affordability on the back of this guide.

†Certain restrictions apply. Terms and conditions on **AUSTEDOcardform.com**.

IMPORTANT SAFETY INFORMATION (Continued)

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Switching patients to one pill, once-daily AUSTEDO XR

Switch from:

- AUSTEDO BID to AUSTEDO XR at same total daily dose (at next fill)[2]
- Tetrabenazine to AUSTEDO XR overnight at half total dose of tetrabenazine[2]

Transition quick reference: Weekly titration for AUSTEDO BID and AUSTEDO XR[2]

Week	AUSTEDO BID dose/ pill count	AUSTEDO XR dose/ pill count
1	**6 mg BID** (14 tablets total) SD 6 + SD 6	**12 mg once daily** (7 tablets total) Q12
2	**9 mg BID** (14 tablets total) SD 9 + SD 9	**18 mg once daily** (7 tablets total) Q18
3	**12 mg BID** (14 tablets total) SD 12 + SD 12	**24 mg once daily** (7 tablets total) Q24
4	**15 mg BID** (28 tablets total) SD 6 + SD 6 + SD 9 + SD 9	**30 mg once daily** (7 tablets total) Q30
5	**18 mg BID** (28 tablets total) SD 9 + SD 9 + SD 9 + SD 9	**36 mg once daily** (7 tablets total) Q36
6	**21 mg BID** (28 tablets total) SD 9 + SD 9 + SD 12 + SD 12	**42 mg once daily** (7 tablets total) Q42
7	**24 mg BID** (28 tablets total) SD 12 + SD 12 + SD 12 + SD 12	**48 mg once daily** (7 tablets total) Q48

This chart follows the standard titration schedule for AUSTEDO and AUSTEDO XR. Not all patients will follow the same schedule, so be sure to confirm patients' current dose with their providers.
Tablets not shown at actual size.

For patients with Huntington's disease (HD) chorea: Recommended initial dose following switch at ~50% of daily tetrabenazine dose.[2]

IMPORTANT SAFETY INFORMATION (Continued)

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.